International Clinical Trial: A Prospective, Single-Arm Investigator-Initiated Trial to Evaluate the Efficacy and Safety of Epalrestat Combined with Toripalimab plus Bevacizumab as First-Line Therapy for Chemotherapy-Ineligible or Chemotherapy-Intolerant Patients with Unresectable, Metastatic, Locally Advanced or Advanced Non-Small Cell Lung Cancer

Geneva, Feb. 2 -- International Clinical Trials Registry received information related to the study (ChiCTR2600117468) titled 'A Prospective, Single-Arm Investigator-Initiated Trial to Evaluate the Efficacy and Safety of Epalrestat Combined with Toripalimab plus Bevacizumab as First-Line Therapy for Chemotherapy-Ineligible or Chemotherapy-Intolerant Patients with Unresectable, Metastatic, Locally Advanced or Advanced Non-Small Cell Lung Cancer' on Jan. 23.

Study Type: Interventional study

Study Design: Single arm

Primary Sponsor: The Affiliated Hospital of Qingdao University

Condition: Non-Small Cell Lung Cancer (NSCLC)

Recruitment Status: Recruiting

Phase: 2

Date of First Enrollment: 2026-01-23

Target Sample Size: Interventio...